Who
Michael Celano
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Larimar Therapeutics; Director, OraSure Technologies; Chief Operating Officer, Recro Pharma; Chief Financial Officer, Kensey Nash.
In numbers
- Trades disclosed
- 90
- Buys
- 4
- Sells
- 4
- Bought
- $218K
- Sold
- $1.1M
- Companies
- 4
- Companies where not an officer
- 1
- First trade
- 4 Oct 2006
- Last trade
- 26 Jan 2026
- Last filed
- 27 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 Jan 2026filed 27 Jan 2026 | LRMR Larimar TherapeuticsBiotechnology | SEC FORM 4 Code A | —37,604 at $0.00 | filing |
| 26 Jan 2026filed 27 Jan 2026 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —225,622 at $0.00 | filing |
| 26 Jan 2026filed 27 Jan 2026 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —225,622 at $0.00 | filing |
| 26 Jan 2026filed 27 Jan 2026 | LRMR Larimar TherapeuticsBiotechnology | SEC FORM 4 Code A | —37,604 at $0.00 | filing |
| 22 Jan 2025filed 24 Jan 2025 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —205,111 at $0.00 | filing |
| 22 Jan 2025filed 24 Jan 2025 | LRMR Larimar TherapeuticsBiotechnology | SEC FORM 4 Code A | —34,185 at $0.00 | filing |
| 17 Jan 2024filed 19 Jan 2024 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —187,500 at $0.00 | filing |
| 17 Jan 2024filed 19 Jan 2024 | LRMR Larimar TherapeuticsBiotechnology | SEC FORM 4 Code A | —31,250 at $0.00 | filing |
| 17 May 2023filed 18 May 2023 | LRMR Larimar TherapeuticsBiotechnology | SEC FORM 4 Bought | $19K5,000 at $3.73 | filing |
| 31 Jan 2023filed 2 Feb 2023 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 31 Jan 2023filed 2 Feb 2023 | LRMR Larimar TherapeuticsBiotechnology | SEC FORM 4 Code A | —76,000 at $0.00 | filing |
| 16 Sep 2022filed 19 Sep 2022 | LRMR Larimar TherapeuticsBiotechnology | SEC FORM 4 Bought | $100K31,746 at $3.15 | filing |
| 12 Aug 2022filed 16 Aug 2022 | OSUR OraSure TechnologiesMedical Devices | SEC FORM 4 Bought | $54K12,000 at $4.49 | filing |
| 16 May 2022filed 18 May 2022 | OSUR OraSure TechnologiesMedical Devices | SEC FORM 4 Code F | $18K3,399 at $5.25 | filing |
| 16 May 2022filed 18 May 2022 | OSUR OraSure TechnologiesMedical Devices | SEC FORM 4 Code A | $130K24,762 at $5.25 | filing |
| 10 May 2022filed 12 May 2022 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 18 Jan 2022filed 20 Jan 2022 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 18 May 2021filed 19 May 2021 | OSUR OraSure TechnologiesMedical Devices | SEC FORM 4 Code A | $130K13,559 at $9.59 | filing |
| 17 May 2021filed 19 May 2021 | OSUR OraSure TechnologiesMedical Devices | SEC FORM 4 Code F | $19K2,041 at $9.50 | filing |
| 19 Jan 2021filed 21 Jan 2021 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.